Brazil Says Paraguay’s Weight-Loss Pens Are Not the Same Drug
Health
Key Facts
—The notice. Anvisa, Brazil’s medicines regulator, published a formal fact-check on 6 July under the heading that the pens showed no equivalence.
—What was tested. A Unicamp toxicology centre checked only the presence, concentration and molecular structure of tirzepatide in smuggled vials.
—What was not. Impurities, contaminants, degradation, sterility, heavy metals and, crucially, bioavailability.
—The factories. The Paraguayan manufacturers’ production lines have never been inspected or certified for good manufacturing practice by Anvisa.
—The paperwork gap. Brazil demands a full international dossier. Paraguay accepts summaries of efficacy and safety studies for new medicines.
—The status. None of the pens is registered in Brazil, and no Paraguayan laboratory has applied for registration.
A Brazilian university found the right molecule inside the Paraguay weight-loss pens that thousands of people carry back across the border. Within forty-eight hours the country’s medicines regulator published a formal correction, because finding the molecule and proving the medicine are not the same act.
The pens in question are sold in Paraguay as versions of tirzepatide, the active ingredient in Mounjaro. They cost a fraction of the Brazilian price, and they are not legal to bring in.
On the sixth of July the agency filed its response under a category it reserves for disinformation. Its own framing was blunt.
What the Paraguay weight-loss pens study actually measured
The laboratory involved was a poisons information centre at the University of Campinas, and it did three things. It confirmed the substance was present, measured its concentration, and checked its molecular structure.
Read the regulator’s list of what it did not do. No analysis of impurities, no contaminants, no product degradation, no sterility, no heavy metals.
Then comes the sentence that carries the whole argument. The agency wrote that “the test did not evaluate bioavailability”, which it calls the single most relevant piece of evidence for saying one medicine behaves like another.
Bioavailability is the plain question of what your body actually does with a drug. How much is absorbed, what concentration reaches the bloodstream, how long it takes to leave.
Two vials can hold the same molecule at the same strength and still deliver quite different amounts into the blood. That is why regulators require the study to be run at an accredited bioequivalence centre, and the Campinas laboratory is not one.
The paperwork gap that explains the price gap
Here is the part almost nobody explains to foreigners living here. Brazilian registration requires the manufacturer itself to apply, submitting a technical dossier built to an international standard that covers formulation, impurities, quality control, manufacturing process and clinical evidence.
Paraguay’s health authority works from a leaner version of that file. For new medicines it accepts summaries of the efficacy and safety studies rather than the complete clinical reports.
That is a legitimate sovereign choice, and it is also the reason a pen can reach a shelf in Ciudad del Este for a fraction of the Brazilian price. You are not only buying a cheaper medicine, you are buying a shorter file.
Anvisa adds a further point that is easy to miss. Without the manufacturer’s own data on how the drug is synthesised and how it degrades, no outside laboratory can know which impurities to look for in the first place.
A test finds only what it was designed to find. The factories behind these pens have never had their production lines inspected by the Brazilian agency, which saw neither the reports nor the methods used.
The pens do hold valid registration with Paraguay‘s own regulator. What they do not hold is any Brazilian one, and not a single Paraguayan laboratory has yet applied.
That last detail matters more than it sounds. Under Brazilian law the manufacturer must come forward itself, so no amount of favourable testing by a third party can make these products legal.
Why this matters more each month
The regulator also made clear that it was not correcting the newspaper that reported the study. It was correcting what social media had made of it.
The economics that drive the smuggling are shifting fast. Eli Lilly recently cut the Brazilian price of Mounjaro by as much as a third, a starter pack falling to around two thousand two hundred and fifty reais, roughly four hundred and forty dollars, and a Brazilian rival has launched a cheaper local pen.
The patent on semaglutide expires in Brazil this year, and the regulator is working through a queue of applications from domestic makers. Every one of those approvals narrows the gap that makes a border run look sensible.
For a foreign resident the practical position is unglamorous but clear. These medicines belong in a conversation with a doctor and in a prescription filled at a licensed pharmacy, and a product with no Brazilian registration offers you no recourse if something goes wrong.
There is a quieter risk too, and it sits outside the laboratory entirely. An injectable drug carried across a border in a warm car has left the chain of refrigeration and record-keeping that a pharmacy is built to guarantee.
This is also a class of medicine that belongs under supervision rather than beside a bathroom mirror. Dose, monitoring and whether the drug suits you at all are clinical judgements, not shopping decisions.
Do the Paraguay weight-loss pens contain the real drug?
The tested samples did contain tirzepatide. Anvisa says that proves identity, not equivalence, because absorption, purity and sterility were never assessed.
Are they legal in Brazil?
No, none holds Brazilian registration, and no Paraguayan laboratory has applied for one. Selling them in Brazil is irregular.
What should a resident do instead?
Speak to a doctor and buy any prescribed medicine from a licensed pharmacy. Brazilian prices for these drugs have fallen sharply this year.
Frequently Asked Questions
Do the Paraguay weight-loss pens actually contain the real tirzepatide molecule?
Yes, a University of Campinas lab confirmed the molecule was present at the right concentration and structure, but Brazil's regulator says that only proves identity, not that the product works the same way in your body, because absorption, purity, sterility, and bioavailability were never tested.
Are these Paraguayan pens legal to bring into or use in Brazil?
No — none of the pens holds Brazilian registration, and not a single Paraguayan manufacturer has even applied for one, which means bringing them across the border is illegal and gives you no legal recourse if something goes wrong.
Why are the Paraguayan pens so much cheaper than the Brazilian version?
Paraguay's health authority approves new medicines based on summaries of safety and efficacy studies rather than the full clinical reports Brazil requires, and the factories behind the pens have never been inspected by Brazil's regulator — that shorter paperwork process and lack of oversight is a big part of what keeps the price low.
Read More from The Rio Times